

## Executive Summary

Data were collected in 2024 from April-May. Interviews from 2020 onwards were delivered face-to-face as well as via telephone, to reduce the risk of COVID-19 transmission; all interviews prior to 2020 were conducted face-to-face. This methodological change should be factored into all comparisons of data from the 2020-2024 samples, relative to previous years.

### Sample Characteristics

Cannabis and/or Cannabinoid-Related  
Products

Non-Prescribed Ketamine, LSD and  
DMT

